{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:43:48Z","timestamp":1790401428674,"version":"4.1.0"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2020,4,1]]},"DOI":"10.1001\/jamaneurol.2019.4749","type":"journal-article","created":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T11:32:37Z","timestamp":1579606357000},"page":"508","source":"Crossref","is-referenced-by-count":116,"title":["Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography"],"prefix":"10.1001","volume":"77","author":[{"given":"Pierre-Fran\u00e7ois","family":"Meyer","sequence":"first","affiliation":[{"name":"Douglas Mental Health University Institute, Studies on Prevention of Alzheimer's Disease Centre, Montreal, Quebec, Canada"},{"name":"Department of Psychiatry, McGill University, Montreal, Quebec, Canada"},{"name":"McGill Centre for Integrative Neuroscience, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Pichet Binette","sequence":"additional","affiliation":[{"name":"Douglas Mental Health University Institute, Studies on Prevention of Alzheimer's Disease Centre, Montreal, Quebec, Canada"},{"name":"Department of Psychiatry, McGill University, Montreal, Quebec, Canada"},{"name":"McGill Centre for Integrative Neuroscience, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Gonneaud","sequence":"additional","affiliation":[{"name":"Douglas Mental Health University Institute, Studies on Prevention of Alzheimer's Disease Centre, Montreal, Quebec, Canada"},{"name":"Department of Psychiatry, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C. S.","family":"Breitner","sequence":"additional","affiliation":[{"name":"Douglas Mental Health University Institute, Studies on Prevention of Alzheimer's Disease Centre, Montreal, Quebec, Canada"},{"name":"Department of Psychiatry, McGill University, Montreal, Quebec, Canada"},{"name":"McGill Centre for Integrative Neuroscience, McGill University, Montreal, Quebec, Canada"},{"name":"Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Villeneuve","sequence":"additional","affiliation":[{"name":"Douglas Mental Health University Institute, Studies on Prevention of Alzheimer's Disease Centre, Montreal, Quebec, Canada"},{"name":"Department of Psychiatry, McGill University, Montreal, Quebec, Canada"},{"name":"McGill Centre for Integrative Neuroscience, McGill University, Montreal, Quebec, Canada"},{"name":"Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ADNI Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"noi190111r1","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers.","volume":"12","author":"Jack","year":"2013","journal-title":"Lancet Neurol"},{"issue":"9","key":"noi190111r2","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease.","volume":"367","author":"Bateman","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"noi190111r3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease.","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"Pt 3","key":"noi190111r4","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/brain\/awu367","article-title":"Independent information from cerebrospinal fluid amyloid-\u00df and florbetapir imaging in Alzheimer\u2019s disease.","volume":"138","author":"Mattsson","year":"2015","journal-title":"Brain"},{"issue":"Pt 4","key":"noi190111r5","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1093\/brain\/aww015","article-title":"Cerebrospinal fluid analysis detects cerebral amyloid-\u00df accumulation earlier than positron emission tomography.","volume":"139","author":"Palmqvist","year":"2016","journal-title":"Brain"},{"issue":"1","key":"noi190111r6","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41467-017-01150-x","article-title":"Earliest accumulation of \u00df-amyloid occurs within the default-mode network and concurrently affects brain connectivity.","volume":"8","author":"Palmqvist","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"noi190111r7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40478-016-0315-6","article-title":"An autoradiographic evaluation of AV-1451 Tau PET in dementia.","volume":"4","author":"Lowe","year":"2016","journal-title":"Acta Neuropathol Commun"},{"issue":"338","key":"noi190111r8","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf2362","article-title":"Tau and A\u00df imaging, CSF measures, and cognition in Alzheimer\u2019s disease.","volume":"8","author":"Brier","year":"2016","journal-title":"Sci Transl Med"},{"issue":"9","key":"noi190111r9","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1212\/WNL.0000000000003050","article-title":"Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly.","volume":"87","author":"Chhatwal","year":"2016","journal-title":"Neurology"},{"issue":"4","key":"noi190111r10","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1212\/WNL.0000000000004860","article-title":"Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample.","volume":"90","author":"La Joie","year":"2018","journal-title":"Neurology"},{"issue":"5","key":"noi190111r11","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.1212\/WNL.0000000000004887","article-title":"Comparing 18F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease.","volume":"90","author":"Mattsson","year":"2018","journal-title":"Neurology"},{"issue":"3","key":"noi190111r12","doi-asserted-by":"publisher","first-page":"378","DOI":"10.2967\/jnumed.111.090340","article-title":"Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer\u2019s disease and cognitively normal subjects.","volume":"53","author":"Joshi","year":"2012","journal-title":"J Nucl Med"},{"issue":"5","key":"noi190111r13","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","article-title":"PET imaging of tau deposition in the aging human brain.","volume":"89","author":"Sch\u00f6ll","year":"2016","journal-title":"Neuron"},{"issue":"4","key":"noi190111r14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes.","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol"},{"issue":"3","key":"noi190111r15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jama.2010.2008","article-title":"Use of florbetapir-PET for imaging beta-amyloid pathology.","volume":"305","author":"Clark","year":"2011","journal-title":"JAMA"},{"issue":"11","key":"noi190111r16","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jama.2018.12917","article-title":"Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders.","volume":"320","author":"Ossenkoppele","year":"2018","journal-title":"JAMA"},{"issue":"5","key":"noi190111r17","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jalz.2015.09.009","article-title":"Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of \u00df-amyloid (1-42) in human cerebrospinal fluid.","volume":"12","author":"Bittner","year":"2016","journal-title":"Alzheimers Dement"},{"issue":"11","key":"noi190111r18","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.jalz.2018.01.013","article-title":"Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging.","volume":"14","author":"Schindler","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"8","key":"noi190111r19","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/acn3.81","article-title":"Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer\u2019s disease.","volume":"1","author":"Mattsson","year":"2014","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"noi190111r20","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s11682-012-9176-1","article-title":"A composite score for executive functioning, validated in Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment.","volume":"6","author":"Gibbons","year":"2012","journal-title":"Brain Imaging Behav"},{"issue":"4","key":"noi190111r21","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s11682-012-9186-z","article-title":"Development and assessment of a composite score for memory in the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI).","volume":"6","author":"Crane","year":"2012","journal-title":"Brain Imaging Behav"},{"issue":"9","key":"noi190111r22","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.15252\/emmm.201707809","article-title":"18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer\u2019s disease.","volume":"9","author":"Mattsson","year":"2017","journal-title":"EMBO Mol Med"},{"key":"noi190111r23","article-title":"Intermediate flortaucipir uptake is associated with a beta-PET and CSF-tau in asymptomatic adults.","author":"McSweeney","journal-title":"Neurology"},{"issue":"1","key":"noi190111r24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S1474-4422(15)00323-3","article-title":"Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study.","volume":"15","author":"Jack","year":"2016","journal-title":"Lancet Neurol"},{"issue":"6","key":"noi190111r25","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1001\/jamaneurol.2016.0194","article-title":"Hypothetical preclinical Alzheimer disease groups and longitudinal cognitive change.","volume":"73","author":"Soldan","year":"2016","journal-title":"JAMA Neurol"},{"issue":"14","key":"noi190111r26","doi-asserted-by":"publisher","first-page":"e1567","DOI":"10.1212\/WNL.0000000000007248","article-title":"ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes.","volume":"92","author":"Soldan","year":"2019","journal-title":"Neurology"},{"issue":"10","key":"noi190111r27","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/S1474-4422(16)30125-9","article-title":"Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer\u2019s disease pathophysiology (SNAP) or Alzheimer\u2019s disease pathology: a longitudinal study.","volume":"15","author":"Burnham","year":"2016","journal-title":"Lancet Neurol"},{"issue":"7691","key":"noi190111r28","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u00df biomarkers for Alzheimer\u2019s disease.","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"issue":"4","key":"noi190111r29","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40336-018-0290-y","article-title":"The development and validation of tau PET tracers: current status and future directions.","volume":"6","author":"Okamura","year":"2018","journal-title":"Clin Transl Imaging"},{"key":"noi190111r30","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.dadm.2018.03.004","article-title":"Challenges associated with biomarker-based classification systems for Alzheimer\u2019s disease.","volume":"10","author":"Ill\u00e1n-Gala","year":"2018","journal-title":"Alzheimers Dement (Amst)"},{"issue":"Pt 10","key":"noi190111r31","article-title":"No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer\u2019s disease.","volume":"130","author":"Buerger","year":"2007","journal-title":"Brain"},{"issue":"Pt 9","key":"noi190111r32","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1093\/brain\/awm136","article-title":"No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer\u2019s disease.","volume":"130","author":"Engelborghs","year":"2007","journal-title":"Brain"},{"issue":"4","key":"noi190111r33","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00401-017-1740-8","article-title":"[F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging.","volume":"134","author":"Marqui\u00e9","year":"2017","journal-title":"Acta Neuropathol"},{"key":"noi190111r34","article-title":"Correlation of in vivo [18F]flortaucipir with postmortem alzheimer disease tau pathology.","author":"Smith","year":"2018","journal-title":"JAMA Neurol"},{"issue":"8","key":"noi190111r35","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/archneur.59.8.1267","article-title":"Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.","volume":"59","author":"Buerger","year":"2002","journal-title":"Arch Neurol"},{"issue":"1","key":"noi190111r36","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1001\/archpsyc.61.1.95","article-title":"Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.","volume":"61","author":"Hampel","year":"2004","journal-title":"Arch Gen Psychiatry"},{"issue":"pt 11","key":"noi190111r37","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1093\/brain\/awl269","article-title":"CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer\u2019s disease.","volume":"129","author":"Buerger","year":"2006","journal-title":"Brain"},{"issue":"3 pt 1","key":"noi190111r38","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1212\/WNL.42.3.631","article-title":"Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer\u2019s disease.","volume":"42","author":"Arriagada","year":"1992","journal-title":"Neurology"},{"issue":"7","key":"noi190111r39","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","article-title":"Tau-targeting therapies for Alzheimer disease.","volume":"14","author":"Congdon","year":"2018","journal-title":"Nat Rev Neurol"},{"issue":"226","key":"noi190111r40","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007901","article-title":"Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer\u2019s disease.","volume":"6","author":"Fagan","year":"2014","journal-title":"Sci Transl Med"},{"issue":"14","key":"noi190111r41","doi-asserted-by":"publisher","first-page":"e1295","DOI":"10.1212\/WNL.0000000000006277","article-title":"Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease.","volume":"91","author":"McDade","year":"2018","journal-title":"Neurology"},{"issue":"6","key":"noi190111r42","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1093\/brain\/awz090","article-title":"A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer\u2019s disease dementia.","volume":"142","author":"Pontecorvo","year":"2019","journal-title":"Brain"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2758654\/jamaneurology_meyer_2020_oi_190111_1611354550.10529.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T20:43:47Z","timestamp":1611607427000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2758654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2019.4749","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,1]]}}}